title: [PET/CT in breast cancer: an update].
abstract: The authors discuss the various roles of 18F-FDG PET/CT in the management of breast cancer. Roles of new tracers such as F-18 fluoro-L-thymidine (a marker of cell proliferation), 18-fluoro-17-B-estradiol (marker of estrogen receptor) and sodium fluoride (marker of bone matrix) are also mentioned. There is little justification for the use of FDG-PET/CT in patient with clinically T1 (< or = 2 cm) N0 tumours. Notably, it cannot be used as a substitute to SLNB "sentinel lymph node biopsy" for axillary staging due to limited sensitivity for the detection of small metastases. The case is different in higher risk patients, and especially so in patients with locally advanced disease. FDG-PET/CT in these patients might depict lymph node involvement in the level III of Berg or in supraclavicular or internal mammary basins. It might also uncover occult distant metastases, notably, early osteomedullary infiltration. Thus, for these tumors, initial PET/CT can enable better intramodality treatment planning or a change in treatment. PET/CT as a whole-body examination is also very efficient in case of suspicion of recurrence. On the other hand, many studies show that this functional imaging could be used to assess early response to neoadjuvant chemotherapy or to chemotherapy of metastatic disease. 18FDG-PET/CT could thus become an unavoidable modality to answer various clinical situations.
authors.affiliation: Service de médecine nucléaire, Pôle imagerie cancérologie PIC, hôpital Saint-Louis, Assistance publique des Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75475 Paris cedex 10, France. dgroheux@yahoo.fr
authors.forename: D
authors.initials: D
authors.lastname: Groheux
authors.forename: J-L
authors.initials: JL
authors.lastname: Moretti
authors.forename: S
authors.initials: S
authors.lastname: Giacchetti
authors.forename: E
authors.initials: E
authors.lastname: Hindié
authors.forename: P
authors.initials: P
authors.lastname: Teyton
authors.forename: C
authors.initials: C
authors.lastname: Cuvier
authors.forename: G
authors.initials: G
authors.lastname: Bousquet
authors.forename: J-L
authors.initials: JL
authors.lastname: Misset
authors.forename: C
authors.initials: C
authors.lastname: Boin
authors.forename: M
authors.initials: M
authors.lastname: Espié
mesh_terms: D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy; D015224:Dideoxynucleosides; D004958:Estradiol / Q000031:analogs & derivatives; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008197:Lymph Node Excision; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012969:Sodium Fluoride; D016896:Treatment Outcome
chemical_list: C545716:18-fluoro-17-estradiol; D015224:Dideoxynucleosides; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D004958:Estradiol; D012969:Sodium Fluoride; C002854:alovudine